The Selexis SUREtechnology Platform™ improves the way cells are used in the discovery, development and manufacturing of recombinant proteins and drugs by providing key significant advantages over traditional approaches including:
- Speed
- 3 weeks for Selexis SUREpools™,
- 12 weeks for Selexis SUREclones™
- High Yield
- High long-term levels
- Typically > 1 g/L for all proteins
- 2-5 g/L for monoclonal antibodies
- Increase in protein expression levels by up to 20 fold
- High long-term levels
- Stability
- Not associated with chromosomal rearrangements nor chromosomal breaks
- Long-term expression of therapeutic proteins over 60 generations
- Single site integration
- Flexible
- Very effective in a variety of cell lines
- >500 recombinant protein cell lines-capacity for screening campaigns
- Proven
- More than 20 Selexis cell lines are in clinical trials up to Phase II
- Technology has been and is currently being used by more than 100 companies worldwide
